Stocktoria
Edwards Lifesciences Corp EW
NYSE · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies · website · IPO 2000-03-27 · LEI
Edwards Lifesciences Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1B | $5.4B | $5.0B | $4.5B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B |
| Gross profit | $4.7B | $4.3B | $4.0B | $3.7B | $4.0B | $3.3B | $3.2B | $2.8B | $2.6B | $2.2B |
| R&D expense | $1.1B | $1.1B | $962.9M | $843.6M | $903.1M | $760.7M | $752.7M | $622.2M | $552.6M | $442.2M |
| SG&A expense | $2.1B | $1.8B | $1.6B | $1.4B | $1.5B | $1.2B | $1.2B | $1.1B | $990.8M | $904.7M |
| Operating income | $1.3B | $1.4B | $1.3B | $1.5B | $1.7B | $897.6M | $1.1B | $748.2M | $1.1B | $751.2M |
| Interest expense | — | — | $17.6M | $19.2M | $18.4M | $15.8M | $20.7M | $29.9M | $23.2M | $19.2M |
| Income tax | $216.9M | $152.1M | $152.4M | $195.5M | $198.9M | $93.3M | $119.6M | $39.2M | $451.3M | $168.4M |
| Net income | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | — | — | — | — | — |
| EPS (diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.90 | $0.87 |
| Operating cash flow | $1.6B | $542.3M | $895.8M | $1.2B | $1.7B | $1.1B | $1.2B | $926.7M | $1.0B | $704.4M |
| Free cash flow | $1.3B | $289.9M | $642.8M | $973.6M | $1.4B | $647.3M | $928.5M | $688.0M | $832.6M | $528.3M |
| Cash & equivalents | $2.9B | $3.0B | $1.1B | $769.0M | $862.8M | $1.2B | $1.2B | $714.1M | $818.3M | $930.1M |
| Inventory | $1.1B | $1.1B | $903.5M | $875.5M | $726.7M | $802.3M | $640.9M | $607.0M | $554.9M | $396.6M |
| Total assets | $13.7B | $13.1B | $9.4B | $8.3B | $8.5B | $7.2B | $6.5B | $5.3B | $5.7B | $4.5B |
| Total liabilities | $3.4B | $3.0B | $2.6B | $2.5B | $2.7B | $2.7B | — | — | — | — |
| Shareholders' equity | $10.3B | $10.1B | $6.7B | $5.8B | $5.8B | $4.6B | $4.1B | $3.1B | $3.0B | $2.6B |
Growth · year-over-year · Revenue CAGR 8.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +11.5% | +8.6% | +12.2% | -14.7% | +19.3% | +0.9% | +16.8% | +8.4% | +15.9% | +18.8% |
| Net income growth | -74.3% | +197.7% | -7.9% | +1.3% | — | — | — | — | — | — |
| EPS growth | -73.7% | +203.0% | -5.7% | +2.5% | +83.1% | -20.7% | +45.1% | +25.6% | +3.4% | +16.0% |
| Free cash flow growth | +360.5% | -54.9% | -34.0% | -30.8% | +117.3% | -30.3% | +35.0% | -17.4% | +57.6% | +18.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.